Lipid lowering agents to delay cognitive decline in Alzheimer's disease?

Lipid lowering agents to delay cognitive decline in Alzheimer's disease?

T here is conflicting evidence for a causal relation between cholesterol, its treatment, and the incidence of Alzheimer’s disease. 2 Merely the finding of a reduced incidence of Alzheimer’s disease among statin users does not necessarily imply any beneficial clinical effect of cholesterol lowering in patients with Alzheimer’s disease. This gap in our understanding of the interplay between chole...

Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease.

BACKGROUND Data from epidemiological studies and animal models imply that disturbances in cholesterol metabolism are linked to Alzheimer's disease susceptibility. Lipid lowering agents (LLAs) may have implications for the prevention of Alzheimer's disease. OBJECTIVE To investigate whether LLAs are associated with a slower cognitive decline in Alzheimer's disease. METHODS An observational st...

Lipid lowering agents, cognitive decline, and dementia: the three-city study.

The aim of this prospective cohort study was to evaluate the effects of lipid lowering agent (LLA) intake on cognitive function in 6,830 community-dwelling elderly persons. Cognitive performance (global cognitive functioning, visual memory, verbal fluency, psychomotor speed, and executive function), clinical diagnosis of dementia, and fibrate and statin use, were evaluated at baseline, and 2, 4...

Lipid lowering to delay the progression of coronary artery disease.

There is now substantial evidence from outcome trials, in individuals who have clinically manifest coronary artery disease (CAD), confirming the benefits of treating plasma lipids as one of the key factors in retarding the progression of clinical atherosclerotic disease. Over the past decade there have been an increasing number of clinical trials which have evaluated lipid lowering treatments, ...

Guideline on Lipid Lowering agents